FDA leverages AI for faster drug approvals and food reviews
The US FDA is starting to use AI tools like Elsa to help review new drugs and medical devices. After a successful trial, they found these tools can quickly sort through huge amounts of clinical data and highlight what matters, making the whole process much more efficient.
AI can handle repetitive tasks
With AI handling repetitive tasks and flagging inconsistencies, scientists at the FDA can spend less time buried in paperwork and more time making important calls about safety and effectiveness. The agency plans to roll out these tools everywhere by June 2025.
Faster access to new treatments
If all goes well, this move could mean faster access to new treatments—especially for tough conditions like rare diseases or diabetes. Some experts are still cautious about relying too much on AI, but the hope is that smarter reviews will get life-changing meds to people who need them, quicker.